TY - JOUR
T1 - Machine learning-enabled maternal risk assessment for women with pre-eclampsia (the PIERS-ML model)
T2 - a modelling study
AU - PIERS Consortium
AU - Montgomery-Csobán, Tünde
AU - Kavanagh, Kimberley
AU - Murray, Paul
AU - Robertson, Chris
AU - Barry, Sarah J.E.
AU - Vivian Ukah, U.
AU - Payne, Beth A.
AU - Nicolaides, Kypros H.
AU - Syngelaki, Argyro
AU - Ionescu, Olivia
AU - Akolekar, Ranjit
AU - Hutcheon, Jennifer A.
AU - Magee, Laura A.
AU - von Dadelszen, Peter
AU - Brown, Mark A.
AU - Davis, Gregory K.
AU - Parker, Claire
AU - Walters, Barry N.
AU - Sass, Nelson
AU - Ansermino, J. Mark
AU - Cao, Vivien
AU - Cundiff, Geoffrey W.
AU - von Dadelszen, Emma C.M.
AU - Douglas, M. Joanne
AU - Dumont, Guy A.
AU - Dunsmuir, Dustin T.
AU - Joseph, K. S.
AU - Lalji, Sayrin
AU - Lee, Tang
AU - Li, Jing
AU - Lim, Kenneth I.
AU - Lisonkova, Sarka
AU - Lott, Paula
AU - Menzies, Jennifer M.
AU - Millman, Alexandra L.
AU - Palmer, Lynne
AU - Payne, Beth A.
AU - Qu, Ziguang
AU - Russell, James A.
AU - Sawchuck, Diane
AU - Shaw, Dorothy
AU - Still, D. Keith
AU - Ukah, U. Vivian
AU - Wagner, Brenda
AU - Walley, Keith R.
AU - Hugo, Dany
AU - Gruslin, The late Andrée
AU - Tawagi, George
AU - Smith, Graeme N.
AU - Bhutta, Zulfiqar A.
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2024/4
Y1 - 2024/4
N2 - Background: Affecting 2–4% of pregnancies, pre-eclampsia is a leading cause of maternal death and morbidity worldwide. Using routinely available data, we aimed to develop and validate a novel machine learning-based and clinical setting-responsive time-of-disease model to rule out and rule in adverse maternal outcomes in women presenting with pre-eclampsia. Methods: We used health system, demographic, and clinical data from the day of first assessment with pre-eclampsia to predict a Delphi-derived composite outcome of maternal mortality or severe morbidity within 2 days. Machine learning methods, multiple imputation, and ten-fold cross-validation were used to fit models on a development dataset (75% of combined published data of 8843 patients from 11 low-income, middle-income, and high-income countries). Validation was undertaken on the unseen 25%, and an additional external validation was performed in 2901 inpatient women admitted with pre-eclampsia to two hospitals in south-east England. Predictive risk accuracy was determined by area-under-the-receiver-operator characteristic (AUROC), and risk categories were data-driven and defined by negative (–LR) and positive (+LR) likelihood ratios. Findings: Of 8843 participants, 590 (6·7%) developed the composite adverse maternal outcome within 2 days, 813 (9·2%) within 7 days, and 1083 (12·2%) at any time. An 18-variable random forest-based prediction model, PIERS-ML, was accurate (AUROC 0·80 [95% CI 0·76–0·84] vs the currently used logistic regression model, fullPIERS: AUROC 0·68 [0·63–0·74]) and categorised women into very low risk (–LR <0·1; eight [0·7%] of 1103 women), low risk (–LR 0·1 to 0·2; 321 [29·1%] women), moderate risk (–LR >0·2 and +LR <5·0; 676 [61·3%] women), high risk (+LR 5·0 to 10·0, 87 [7·9%] women), and very high risk (+LR >10·0; 11 [1·0%] women). Adverse maternal event rates were 0% for very low risk, 2% for low risk, 5% for moderate risk, 26% for high risk, and 91% for very high risk within 48 h. The 2901 women in the external validation dataset were accurately classified as being at very low risk (0% with outcomes), low risk (1%), moderate risk (4%), high risk (33%), or very high risk (67%). Interpretation: The PIERS-ML model improves identification of women with pre-eclampsia who are at lowest and greatest risk of severe adverse maternal outcomes within 2 days of assessment, and can support provision of accurate guidance to women, their families, and their maternity care providers. Funding: University of Strathclyde Diversity in Data Linkage Centre for Doctoral Training, the Fetal Medicine Foundation, The Canadian Institutes of Health Research, and the Bill & Melinda Gates Foundation.
AB - Background: Affecting 2–4% of pregnancies, pre-eclampsia is a leading cause of maternal death and morbidity worldwide. Using routinely available data, we aimed to develop and validate a novel machine learning-based and clinical setting-responsive time-of-disease model to rule out and rule in adverse maternal outcomes in women presenting with pre-eclampsia. Methods: We used health system, demographic, and clinical data from the day of first assessment with pre-eclampsia to predict a Delphi-derived composite outcome of maternal mortality or severe morbidity within 2 days. Machine learning methods, multiple imputation, and ten-fold cross-validation were used to fit models on a development dataset (75% of combined published data of 8843 patients from 11 low-income, middle-income, and high-income countries). Validation was undertaken on the unseen 25%, and an additional external validation was performed in 2901 inpatient women admitted with pre-eclampsia to two hospitals in south-east England. Predictive risk accuracy was determined by area-under-the-receiver-operator characteristic (AUROC), and risk categories were data-driven and defined by negative (–LR) and positive (+LR) likelihood ratios. Findings: Of 8843 participants, 590 (6·7%) developed the composite adverse maternal outcome within 2 days, 813 (9·2%) within 7 days, and 1083 (12·2%) at any time. An 18-variable random forest-based prediction model, PIERS-ML, was accurate (AUROC 0·80 [95% CI 0·76–0·84] vs the currently used logistic regression model, fullPIERS: AUROC 0·68 [0·63–0·74]) and categorised women into very low risk (–LR <0·1; eight [0·7%] of 1103 women), low risk (–LR 0·1 to 0·2; 321 [29·1%] women), moderate risk (–LR >0·2 and +LR <5·0; 676 [61·3%] women), high risk (+LR 5·0 to 10·0, 87 [7·9%] women), and very high risk (+LR >10·0; 11 [1·0%] women). Adverse maternal event rates were 0% for very low risk, 2% for low risk, 5% for moderate risk, 26% for high risk, and 91% for very high risk within 48 h. The 2901 women in the external validation dataset were accurately classified as being at very low risk (0% with outcomes), low risk (1%), moderate risk (4%), high risk (33%), or very high risk (67%). Interpretation: The PIERS-ML model improves identification of women with pre-eclampsia who are at lowest and greatest risk of severe adverse maternal outcomes within 2 days of assessment, and can support provision of accurate guidance to women, their families, and their maternity care providers. Funding: University of Strathclyde Diversity in Data Linkage Centre for Doctoral Training, the Fetal Medicine Foundation, The Canadian Institutes of Health Research, and the Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85188631736&partnerID=8YFLogxK
U2 - 10.1016/S2589-7500(23)00267-4
DO - 10.1016/S2589-7500(23)00267-4
M3 - Article
C2 - 38519152
AN - SCOPUS:85188631736
SN - 2589-7500
VL - 6
SP - e238-e250
JO - The Lancet Digital Health
JF - The Lancet Digital Health
IS - 4
ER -